Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics (LUCD) announced that the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines has updated its recommendations to include esophageal precancer screening. The new guidelines now reference professional society guidelines that recommend non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test with EsoCheck® Collection Device, as an acceptable alternative to invasive upper endoscopy for detecting esophageal precancer (Barrett's Esophagus).
This update aligns with the American College of Gastroenterology (ACG) Clinical Guideline and represents a significant step toward recognizing esophageal precancer testing's role in cancer prevention. The company expects this alignment between NCCN Guidelines and gastroenterology society guidelines to positively influence commercial insurance coverage decisions and expand access to EsoGuard testing.
Lucid Diagnostics (LUCD) ha annunciato che le Linee Guida Cliniche del National Comprehensive Cancer Network® (NCCN) sono state aggiornate per includere lo screening per il precancro esofageo. Le nuove linee guida ora fanno riferimento alle linee guida delle società professionali che raccomandano il test biomarker non endoscopico, come il test di DNA esofageo EsoGuard® con il dispositivo di raccolta EsoCheck®, come un'alternativa accettabile all'endoscopia superiore invasiva per la rilevazione del precancro esofageo (esofago di Barrett).
Questo aggiornamento è in linea con le Linee Guida Cliniche dell'American College of Gastroenterology (ACG) e rappresenta un passo significativo verso il riconoscimento del ruolo del test per il precancro esofageo nella prevenzione del cancro. L'azienda si aspetta che questo allineamento tra le linee guida NCCN e quelle delle società di gastroenterologia influisca positivamente sulle decisioni di copertura assicurativa commerciale e ampli l'accesso al test EsoGuard.
Lucid Diagnostics (LUCD) anunció que las Guías de Práctica Clínica del National Comprehensive Cancer Network® (NCCN) han sido actualizadas para incluir el cribado de precáncer esofágico. Las nuevas guías ahora hacen referencia a las guías de sociedades profesionales que recomiendan pruebas de biomarcadores no endoscópicas, como la prueba de ADN esofágico EsoGuard® con el dispositivo de recolección EsoCheck®, como una alternativa aceptable a la endoscopia superior invasiva para detectar el precáncer esofágico (esófago de Barrett).
Esta actualización está alineada con las Guías Clínicas del American College of Gastroenterology (ACG) y representa un paso significativo hacia el reconocimiento del papel de las pruebas de precáncer esofágico en la prevención del cáncer. La empresa espera que esta alineación entre las guías de NCCN y las guías de sociedades de gastroenterología influya positivamente en las decisiones de cobertura de seguros comerciales y amplíe el acceso a las pruebas de EsoGuard.
Lucid Diagnostics (LUCD)는 National Comprehensive Cancer Network® (NCCN)의 임상 진료 지침이 식도 전암 선별 검사를 포함하도록 업데이트되었다고 발표했습니다. 새로운 지침은 비내시경 바이오마커 검사를 권장하는 전문 학회 지침을 참조하며, 이는 식도 전암(바렛 식도)을 감지하기 위한 침습적 상부 내시경의 수용 가능한 대안으로 Lucid의 EsoGuard® 식도 DNA 테스트와 EsoCheck® 수집 장치를 포함합니다.
이번 업데이트는 American College of Gastroenterology (ACG)의 임상 지침과 일치하며, 식도 전암 검사 역할을 암 예방에서 인식하는 중요한 단계입니다. 이 회사는 NCCN 지침과 위장병학회 지침 간의 일치가 상업적 보험 보장 결정에 긍정적인 영향을 미치고 EsoGuard 테스트에 대한 접근성을 확대할 것으로 기대하고 있습니다.
Lucid Diagnostics (LUCD) a annoncé que les Directives de Pratique Clinique du National Comprehensive Cancer Network® (NCCN) ont été mises à jour pour inclure le dépistage du précancer œsophagien. Les nouvelles directives font désormais référence aux recommandations des sociétés professionnelles qui recommandent le test de biomarqueurs non endoscopique, tel que le test ADN œsophagien EsoGuard® avec le dispositif de collecte EsoCheck®, comme une alternative acceptable à l'endoscopie supérieure invasive pour détecter le précancer œsophagien (œsophage de Barrett).
Cette mise à jour est en accord avec les Directives Cliniques de l'American College of Gastroenterology (ACG) et représente un pas significatif vers la reconnaissance du rôle des tests de précancer œsophagien dans la prévention du cancer. L'entreprise s'attend à ce que cet alignement entre les Directives NCCN et les recommandations des sociétés de gastroentérologie influence positivement les décisions de couverture d'assurance commerciale et élargisse l'accès aux tests EsoGuard.
Lucid Diagnostics (LUCD) gab bekannt, dass die klinischen Praxisrichtlinien des National Comprehensive Cancer Network® (NCCN) aktualisiert wurden, um das Screening auf Speiseröhrenpräkanzer zu umfassen. Die neuen Richtlinien verweisen nun auf die Richtlinien professioneller Gesellschaften, die nicht-invasive Biomarker-Tests, wie den EsoGuard® Speiseröhren-DNA-Test mit dem EsoCheck®-Entnahmegerät, als akzeptable Alternative zur invasiven oberen Endoskopie zur Erkennung von Speiseröhrenpräkanzer (Barrett-Ösophagus) empfehlen.
Dieses Update steht im Einklang mit den klinischen Richtlinien des American College of Gastroenterology (ACG) und stellt einen bedeutenden Schritt in Richtung Anerkennung der Rolle von Tests auf Speiseröhrenpräkanzer in der Krebsprävention dar. Das Unternehmen erwartet, dass diese Übereinstimmung zwischen den NCCN-Richtlinien und den Richtlinien der Gastroenterologie-Vereinigungen positive Auswirkungen auf Entscheidungen zur kommerziellen Versicherungsdeckung haben und den Zugang zu EsoGuard-Tests erweitern wird.
- NCCN Guidelines now include non-endoscopic biomarker testing as acceptable alternative to endoscopy
- Guidelines alignment expected to drive positive insurance coverage decisions
- Potential expansion of market access for EsoGuard testing
- None.
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy
"This update is an important step towards the recognition of the role of esophageal precancer testing to prevent esophageal cancer," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "The NCCN Guidelines are widely recognized as a key indicator of standards of excellence for cancer care and prevention. We believe the current alignment between these highly influential cancer guidelines and multiple gastroenterology society guidelines on BE screening will help drive positive commercial insurance policy coverage decisions and expand access to EsoGuard esophageal precancer testing."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
About NCCN
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-updated-national-comprehensive-cancer-network-nccn-guidelines-now-include-esophageal-precancer-screening-302407012.html
SOURCE Lucid Diagnostics
FAQ
What is the significance of NCCN including EsoGuard in their updated guidelines?
How will the NCCN guideline update affect LUCD's commercial coverage?
What medical conditions can Lucid's EsoGuard test detect?
Which professional organizations now support non-endoscopic testing like LUCD's EsoGuard?
